GEMSP: A new therapeutic approach to multiple sclerosis

Central Nervous System Agents in Medicinal Chemistry

Volumn 12, Issue 3, 2012, Pages 173-181

  Geffard, Michel ^a,b   Duleu, Sébastien ^a   Bessede, Alban ^a,b   Vigier, Valérie ^c   Bodet, Dominique ^c   Mangas, Arturo ^d   Coveñas, Rafael ^d  

^a Institute for Development of Research on Human Pathology and Therapeutics (IDRPHT)   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c Gemacbio   (France)

^d UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Bacteria; Clinical trials; Fatty acids; GEMSP; Immunoglobulins; Multiple sclerosis; Poly L.lysine

Indexed keywords

5 METHOXYTRYPTAMINE; ALPHA TOCOPHEROL; ALPHA TOCOPHEROL SUCCINATE; AMINO ACID DERIVATIVE; ANTIOXIDANT; ASCORBIC ACID; AUTOANTIGEN; AZELAIC ACID; CHOLESTEROL; CYSTEINE; FATTY ACID; FATTY ACID DERIVATIVE; FREE RADICAL; GLUTARALDEHYDE; HISTAMINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LINOLEIC ACID; METHIONINE; MYRISTIC ACID; OLEIC ACID; PALMITIC ACID; POLYLYSINE; REACTIVE OXYGEN METABOLITE; SCAVENGER; STEROL DERIVATIVE; SUCCINIC ACID; TAURINE; UNINDEXED DRUG; VITAMIN;

ABSENCE OF SIDE EFFECTS; ACINETOBACTER; ALLERGIC ENCEPHALOMYELITIS; ARTICLE; AUTOIMMUNE DISEASE; BIOMEDICINE; CELL INFILTRATION; CHLAMYDOPHILA PNEUMONIAE; CHRONIC DISEASE; DISEASE COURSE; DRUG SAFETY; ESCHERICHIA COLI; ETIOLOGY; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; LEUKOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEUS; PSEUDOMONAS AERUGINOSA;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS;

EID: 84866638450     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/187152412802430110     Document Type: Article

References (74)

1. Weinshenker, B.G.; Bulman, D.; Carriere, W.; Baskerville, J.; Ebers, G.C. A comparison of sporadic and familial multiple sclerosis. Neurology, 1990, 40, 1354-1358.
2. Lubin, B.; Van Whitlock, R.; Dale, T.M.; Riesenmy, K.R.; Desouza, E. Further study of the diagnostic and screening efficiency of the ST-Depression adjective check lists. J. Clin. Psychol., 1996, 52, 26-31.
3. Minagar, A.; Alexander J.S. Blood-brain barrier disruption in multiple sclerosis. Mult. Scler., 2003, 9, 540-549.
4. Liu, B.; Gao, H.M.; Wang, J.Y.; Jeohn, G.H.; Cooper, C.L.; Hong, J.S. Role of nitric oxide in inflammation-mediated neurodegeneration. Ann. N.Y. Acad. Sci., 2002, 962, 318-331.
5. Geffard, M.; de Bisschop, L.; Duleu, S.; Pouns, O.; Ferran, G.; Bessede, A.; Hassaine, N.; Autran, J-L.; Bodet, D.; Mangas, A.; Coveñas, R. Endotherapia. AIAAMC, 2010, 9, 197-211.
6. Geffard, M.; de Bisschop, L.; Duleu, S.; Hassaine, N.; Mangas, A.; Coveñas, R. Endotherapia: a new frontier in the treatment of multiple sclerosis and other chronic diseases. Discov. Med., 2010, 10, 443-451.
7. Duleu, S.; Van Der Velden, C.; Salauze, L.; Lagroye, I.; Veyret, B.; Tranchant, M.C.; Geffard, M. Circulating antibodies to NO-and HNOO-modified antigens in amyotrophic lateral sclerosis, Alzheimer's disease and multiple sclerosis. Immunoanal. Biol. Spéc., 2007, 22, 273-281.
8. Boullerne, A.; Petry, K.G.; Meynard, M.; Geffard, M. Indirect evidence for NO involvement in multiple sclerosis by characterization of circulating antibodies directed against conjugated S-nitrosocysteine. J. Neuroimmunol., 1995, 60, 117-124
9. Geffard, M.; Duleu, S.; Bessede, A.; Coveñas, R.; Mangas, A. In: Multiple Sclerosis: a New Paradigm; Geffard, Ed.; Nova Science Publishers: New York, 2011; in press.
10. Engelhardt, B.; Kappos, L. Natalizumab. Integrins in multiple sclerosis. Neurodegener Dis., 2008, 5, 16-22.
11. Fox, E.J. Management of worsening multiple sclerosis with mitoxantrone: a review. Clin. Ther., 2006, 28, 461-474.
12. Le Page, E.; Leray, E.; Taurin, G.; Coustans, M.; Chaperon, J.; Morrissey, S.P.; Edan, G. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J. Neurol. Neurosurg. Psychiatry, 2008, 79, 52-56.
13. Goodin, D.S.; Cohen, B.A.; O'Connor, P.; Kappos, L.; Stevens, J.C. Assessment. The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review). Neurology, 2008, 71, 766-773.
14. Hartung, H.P. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol., 2009, 8, 28-31.
15. Mullen, J.T.; Vartanian, T.K.; Atkins, M.B. Melanoma complicating treatment with natalizumab for multiple sclerosis. N. Engl. J. Med., 2008, 358, 647-648.
16. Arnon, R.; Sela, M. Immunomodulation by the copolymer glatiramer acetate. J. Mol. Recognit., 2003, 16, 412-421.
17. Maier, K.; Kuhnert, A.V.; Taheri, N.; Sättler, M.B.; Storch, M.K.; Williams, S.K.; Bähr, M.; Diem, R. Effects of glatiramer acetate and interferon-α on neurodegeneration in a model of Multiple sclerosis: a comparative study. Am. J. Pathol., 2006, 169, 1353-1364.
18. Fromont, A.; Moreau, T. Sclérose en plaques: traitements d'aujourd'hui et de demain. Médecine, 2007, 3, 61-66.
19. Hurwitz, B.J.; Jeffery, D.; Arnason, B.; Bigley, K.; Coyle, P.; Goodin, D.; Kaba, S.; Kirzinger, S.; Lynch, S.; Mandler, R.; Mikol, D.; Rammohan, K.; Sater, R.; Sriram, S.; Thrower, B.; Boateng, F.; Jakobs, P.; Wash, M.B.; Bogumil, T. Tolerability and safety profile of 12-to 28-week treatment with interferon beta-1b 250 and 500 μg QOD in patients with relapsing-remitting multiple sclerosis: A multicenter, randomized, double-blind, parallel group pilot study. Clin. Ther., 2008, 30, 1102-1112.
20. Calabresi, P.A. Diagnosis and management of multiple sclerosis. Am. Fam. Phys., 2004, 70, 1935-1944.
21. Coles, A.J.; Compston, D.A.; Selmaj, K.W.; Lake, S.L.; Moran, S.; Margolin, D.H.; Norris, K.; Tandon, P.K. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med., 2008, 359, 1786-1801.
22. Peleg, A.Y.; Husain, S.; Kwak, E.J.; Silveira, F.P.; Ndirangu, M.; Tran, J.; Shutt, K.A.; Shapiro, R.; Thai, N.; Abu-Elmagd, K.; McCurry, K.R.; Marcos, A; Paterson, D.L. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin. Infect. Dis., 2007, 44, 204-212.
23. Mangas, A.; Coveñas, R.; Geffard, M. New drug therapies for multiple sclerosis. Curr. Opin. Neurol., 2010, 23, 287-292.
24. Ebringer, A.; Hughes, L.; Rashid, T.; Wilson, C. Acinetobacter immune responses in multiple sclerosis. Etiopathogenetic role and its possible use as a diagnostic marker. Arch. Neurol., 2005, 62, 33-36.
25. Hughes, L.E.; Bonell, S.; Natt, R.S.; Wilson, C.; Tiwana, H.; Ebringer, A.; Cunningham, P.; Chamoun, V.; Thompson, E.J.; Croker, J.; Vowles, J. Antibody responses to Acinetobacter spp. and Pseudomonas aeruginosa in multiple sclerosis: prospects for diagnosis using the myelin-Acinetobacter-neurofilament antibody index. Clin. Diagn. Lab. Immun., 2001, 8, 1181-1188.
26. Furrows, S.J.; Hartley, J.C.; Bell, J.; Silver, N.; Losseff, N.; Stevenson, S.; Chapman, M.; Thompson, E.J.; Ridgway, G.L.; Giovannoni, G. Chlamydophila pneumoniae infection of the central nervous system in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry, 2004, 75, 152-154.
27. Schiffenbauer, J.; Johnson, H.M.; Butfiloski, E.J.; Wegrzyn, L.; Soos, J.M. Staphylococcal enterotoxins can reactivate experimental allergic encephalomyelitis. Proc. Natl. Acad. Sci. USA, 1993, 90, 8543-8546.
28. Brocke, S.; Gaur, A.; Piercy, C.; Gautam, A.; Gijbels, K.; Fathman, C.G.; Steinman, L. Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigens. Nature, 1993, 365, 642-644.
29. Bohatschek, M.; Werner, A.; Raivich, G. Systemic LPS injection leads to granulocyte influx into normal and injured brain: effects of ICAM-1 deficiency. Exp. Neurol., 2001, 172, 137-152.
30. Lehnardt, S.; Lachance, C.; Patrizi, S.; Lefebvre, S.; Follett, P.L.; Jensen, F.E.; Rosenberg, P.A.; Volpe, J.J.; Vartanian, T. The tolllike receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J. Neurosci., 2002, 22, 2478-2486.
31. Akira, S.; Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol., 2004, 4, 499-511.
32. Bechtold, D.A.; Smith, K.J. Sodium-mediated axonal degeneration in inflammatory demyelinating disease. J. Neurol. Sci., 2005, 233, 27-35.
33. Kohn, F.R.; Kung, A.H.C. Role of endotoxin in acite inflammation induced by Gram-negative bacteria: specific inhibition of Lipopolysaccharide-mediated responses with an amino-terminal fragment of bacterial/permeability increasing protein. Infect. Immun., 1995, 63, 333-339.
34. Pouns, O.; Mangas, A.; Coveñas, R.; Geffard, M. Circulating antibodies directed against "polycyclic aromatic hydrocarbon-like" structures in the sera of cancer patients. Cancer Epidemiol., 2009, 33, 3-8.
35. Geffard, M.; Bodet, D.; Martinet, Y.; Dabadie, M.P. Intérêt de l'évaluation d'IgM et d'IgA spécifiques circulant dans le sérum de malades atteints de sclérose en plaques (SEP). Immunoanal. Biol. Spéc., 2002, 17, 302-310.
36. Mahalingam, S; Lidbury, B.A. Antibody-dependent enhancement of infection: bacteria do it too. Trends Immunol., 2003, 24, 465-467.
37. Geffard, M.; Bodet, D.; Claudepierre, P.; Metzger, J.M.; Sibilia, J. Anticorps sériques circulants dirigés contre des antigènes modifiés par le NO dans les affections neurologiques et rhumatismales. Immunoanal. Biol. Spéc., 1998, 13, 209-217.
38. Maneta-Peyret, L.; Daverat, P.; Geffard, M.; Cassagne, C.; Orgogozo, J.M. Natural seric anti-fatty acid antibodies in multiple sclerosis. Neurosci. Lett., 1987, 80, 235-239.
39. Daverat, P.; Geffard, M.; Orgogozo, J.M. Identification and characterization of anti-conjugated azelaic acid antibodies in multiple sclerosis. J. Neuroimmunol., 1989, 22, 129-134.
40. Salauze, L.; Van Der Velden, C.; Lagroye, I.; Veyret, B.; Geffard, M. Circulating antibodies to cysteinyl catecholamines in amyotrophic lateral sclerosis and Parkinsonians patients. Amyotrophic Lateral Scler. Other Motor Neuron Disord., 2005, 6, 226-233.
41. Duleu, S.; Mangas, A.; Poulletier De Gannes, F.; Tranchant, M.C.; Geffard, M. Circulating antibodies to conjugated tryptophan derivatives of IDO pathway in amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease and multiple sclerosis patients. Immunoanal. Biol. Spéc., 2008, 23, 27-34.
42. Geffard, M.; Bodet, D.; Dabadie, M.P.; Arnould, L. Identification d'anticorps circulants dans le sérum de patientes porteuses de tumeurs malignes du sein. Immunoanal. Biol. Spéc., 2003, 18, 248-253.
43. Amara, A.; Chaugier, C.; Ragnaud, J-M.; Geffard, M. Circulating autoantibodies directed against conjugated fatty acids in sera of HIV-1 infected patients. Clin. Exp. Immunol., 1994, 96, 379-383.
44. Amara, A.; Constans, J.; Chaugier, C.; Sebban, A.; Dubourg, L.; Peuchant, E.; Pellegrin, J.L.; Leng, B.; Conri, C.; Geffard, M. Autoantibodies to malondialdehyde-modified epitope in connective tissue diseases and vasculitides. Clin. Exp. Immunol., 1995, 101, 1-6.
45. Shih, I.L.; Van, Y.T.; Shen, M.H. Biomedical applications of chemically and microbiologically synthesized poly (glutamic acid) and poly (lysine). Mini Rev. Med. Chem., 2004, 4, 179-188.
46. Geffard, M. "Use of conjugated of fatty acids to poly-L-lysine aim to struggle pathogenic microorganisms". Patent registered on the 07/03/2007 under n° 0753675. International extension was submitted on the 10/16/2008 under the number N° WO 2008/122741, having as object use of derivated fatty acid and of poly-L-lysine to struggle against the pathogenic microorganisms.
47. Mangas, A.; Coveñas, R.; Bodet, D.; Dabadie, M.P.; Glaize, G.; Geffard, M. Evaluation of the effects of a new drug on brain leukocyte infiltration in an experimental model of autoimmune encephalomyelitis. Lett. Drug Des. Discov., 2006, 3, 138-148.
48. Mangas, A.; Coveñas, R.; Bodet, D.; de León, M.; Duleu, S.; Geffard M. Evaluation of the effects of a new drug candidate (GEMSP) in a chronic EAE model. Int. J. Biol. Sci., 2008, 4, 150-160.
49. Mangas, A.; Coveñas, R.; Bodet, D.; Duleu, S.; Geffard, M. A new drug candidate (GEMSP) for multiple sclerosis. Curr. Med. Chem., 2009, 16, 3203-3214.
50. Nicaise, C.; Coupier, J.; Dabadie, M.P.; De Decker, R.; Mangas, A.; Bodet, D.; Poncelet, L.; Geffard, M.; Pochet, R. Gemals, a new drug candidate, extends lifespan and improves muscular performance in an amyotrophic lateral sclerosis rat model. Amyotroph. Lateral Scler., 2008, 9, 85-90.
51. Ali, M.; Hicks, A.E.R.; Hellewell, P.G.; Thoma, G.; Norman, K.E. Polymers carrying sLex-mimetics are superior inhibitors of Eselectin-dependent leukocyte rolling in vivo. FASEB J., 2004, 18, 152-154.
52. Shen, W.C.; Ryser, H.J. Conjugation of poly-L-lysine to albumin and horseradish peroxidase: a novel method of enhancing the cellular uptake of proteins. Proc. Natl. Acad. Sci. USA, 1978, 75, 1872-1876.
53. Elferink, J.G.R. Changes of plasma membrane permeability in neutrophils treated with polycations. Inflammation, 1991, 15, 103-115.
54. Geffard, M.; Peroteau, J.F.; Duleu, S.; Dabadie, M.P. Anti-bacterial activity of poly-L-lysine conjugates. BMC Proc., 2008, 2,22.
55. Geffard, M.; Tranchant, C.; Fleury, M.; Wiertlewski, S.; Guennoc, A.M.; Dabadie, M.P. GEMSEP1: a new drug candidate for secondary progressive form of multiple sclerosis. Mulp. Scler., 2005, 11, 165.
56. Mangas, A.; Coveñas, R.; Bodet, D.; de León, M.; Geffard, M.; Dabadie, M.P. Evaluation of GEMSP effects on the central nervous system of the Lewis 1a rats in a chronic EAE model. J. Neurol., 2006, 253, 125.
57. Coveñas, R.; Mangas, A.; Jaulain, C.; Geffard, M. In: Molecular and Clinical Neuroscience. Sugaya and Samsam, Eds.; McNeil: Plymouth (USA), 2011; in press.
58. Victor, V.M.; de la Fuente, M. Changes in the superoxide production and other macrophage functions could be related to the mortality of mice with endotoxin-induced oxidative stress. Physiol. Res., 2003, 52, 101-110.
59. van Meeteren, M.E.; Teunissen, C.E.; Dijkstra, C.D.; van Tol, E.A. Antioxidants and polyunsaturated fatty acids in multiple sclerosis. Eur. J. Clin. Nutr., 2005, 59, 1347-1361.
60. Gilgun-Sherki, Y.; Melamed, E.; Offen, D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol., 2004, 251, 261-268.
61. Halliwell, B. Reactive species and antioxidants. Redox biology is a fundamental theme of aerobic life. Plant Physiol., 2006, 141, 312-322.
62. Marracci, G.H.; Jones, R.E.; McKeon, G.P.; Bourdette, D.N. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J. Neuroimmunol., 2002, 131, 104-114.
63. Massacesi, L.; Abbamondi, A.L.; Giorgi, C, Sarlo, F, Lolli, F, Amaducci, L.J. Suppression of experimental allergic encephalomyelitis by retinoic acid. Neurol. Sci., 1987, 80, 55-64.
64. Xu, J.; Drew, P.D. 9-Cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes. J. Neuroimmunol., 2006, 171, 135-144.
65. Helgestad, J.; Storm-Mathisen, I.; Lie, S.O. Vitamin C and thiol reagents promote the in vitro growth of murine granulocyte/macrophage progenitor cells by neutralizing endogenous inhibitor(s). Blut, 1986, 52, 1-8.
66. Iwata-Ichikawa, E.; Kondo, Y.; Miyazaki, I.; Asanuma, M.; Ogawa, N. Glial cells protect neurons against oxidative stress via transcriptional up-regulation of the glutathione synthesis. J. Neurochem., 1999, 72, 2334-2344.
67. Reiter, R.J. Potential biological consequences of excessive light exposure: melatonin suppression, DNA damage, cancer and neurodegenerative diseases. Neuroendocrinol. Lett., 2002, 23, 9-13.
68. Costa, B.; Conti, S.; Giagnoni, G.; Colleoni, M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br. J. Pharmacol., 2002, 137, 413-420.
69. Darlington, L.G.; Stone, T.W. Antioxidants and fatty acids in the amelioration of rheumatoid arthritis and related disorders. Br. J. Nutr., 2001, 85, 251-269.
70. Chang, A.; Tourtellotte, W.W.; Rudick, R.; Trapp, B.D. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med., 2002, 346, 165-173.
71. Di Biase, A.; Salvati, S. Exogenous lipids in myelination and myelination. Kaohsiung J. Med. Sci., 1997, 13, 19-29.
72. Gillson, G.; Wright, J.V.; DeLack, E.; Ballasiotes, G. Transdermal histamine in multiple sclerosis: part one clinical experience. Altern. Med. Rev., 1999, 4, 424-428.
73. Teufel, M.; Saudek, V.; Ledig, J.P.; Bernhardt, A.; Boularand, S.; Carreau, A.; Cairns, N.J.; Carter, C.; Cowley, D.J.; Duverger, D.; Ganzhorn, A.J.; Guenet, C.; Heintzelmann, B.; Laucher, V.; Sauvage, C.; Smirnova, T. Sequence identification and characterization of human carnosinase and a closely related nonspecific dipeptidase. J. Biol. Chem., 2003, 278, 6521-6531.
74. Medina, J.M.; Tabernero, A. Astrocyte-synthesized oleic acid behaves as a neurotrophic factor for neurons. J. Physiol. (Paris), 2002, 96, 265-271.